RE:TIGIT class of checkpoint inhibitors fails with Keytruda August 05, 2024 - Agenus created a TIGIT bispecific antibody candidate to overcome the limitations of anti-TIGIT antibodies. BMS however has terminated the deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program.
https://www.fiercebiotech.com/biotech/bms-ditches-tigit-walking-away-200m-bet-agenus-bispecific